Regeneron Pharmaceuticals Other Non-Current Assets increased by 16.9% to $2.13B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 52.9%, from $1.39B to $2.13B. Over 5 years (FY 2020 to FY 2025), Other Non-Current Assets shows an upward trend with a 61.0% CAGR.
Significant changes may indicate shifts in accounting estimates, tax positions, or non-core asset holdings.
This category includes long-term assets that do not fit into specific classifications like PP&E or intangibles, such as...
Standard line item in most balance sheets, often labeled 'Other non-current assets'.
non_current_assets_other_assets_noncurrent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $142.90M | $145.90M | $222.80M | $262.00M | $269.90M | $320.20M | $336.40M | $349.60M | $393.20M | $409.90M | $444.10M | $470.20M | $993.80M | $1.04B | $1.14B | $1.39B | $1.54B | $1.67B | $1.82B | $2.13B |
| QoQ Change | — | +2.1% | +52.7% | +17.6% | +3.0% | +18.6% | +5.1% | +3.9% | +12.5% | +4.2% | +8.3% | +5.9% | +111.4% | +5.0% | +8.9% | +22.6% | +10.3% | +8.9% | +8.9% | +16.9% |
| YoY Change | — | — | — | — | +88.9% | +119.5% | +51.0% | +33.4% | +45.7% | +28.0% | +32.0% | +34.5% | +152.7% | +154.5% | +155.8% | +196.3% | +54.6% | +60.4% | +60.3% | +52.9% |